Clinical Oncology Week articles from November 2004

Clinical Oncology Week archives from November 2004

Antiestrogenic drug combinations may be used for glioblastoma malignancies.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Antiestrogenic drug combinations may be used for glioblastoma malignancies. According to researchers in Turkey, "The antitumor activity of nonsteroidal antiestrogens on C6 and low passage of human...

Researchers gain insight into mechanism of cancer wasting.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- The often-fatal muscle wasting that accompanies many types of cancer is not simply a loss of muscle proteins generally, but seems to occur through a selective loss of particular muscle proteins,...

Infection site and patient ethnicity affect HPV-induced cancer pathways.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- The site of infection and ethnicity of the patient influence the biological pathways to HPV-induced mucosal cancer. According to published research from Australia, "High-risk human papillomaviruses...

Molecular mechanisms of ATRA in APL determined.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- The antitumor activity of all-trans-retinoic acid (ATRA) in acute promyelocytic leukemia (APL) has been elucidated. ATRA "induces growth inhibition, differentiation, and apoptosis in cancer cells,"...

Laser-induced thermotherapy effective in lung metastases and primary lung tumors.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Laser-induced thermotherapy is effective in lung metastases and primary lung tumors. According to a study from Germany, "We present laser-induced thermotherapy (LITT) of primary and secondary lung...

Slightly increased risk of ischemic stroke found with tamoxifen.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Researchers at Duke University Medical Center have found a slightly elevated risk of ischemic stroke due to a blood clot in the brain in patients treated with tamoxifen, a drug commonly prescribed both...

Oral fluconazole safe/effective empiric treatment for neutropenic fever.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Oral fluconazole is a safe and effective empiric treatment for persistent neutropenic fever. According to a study from Israel, "Neutropenic patients who continue to be febrile despite adequate...

Anticancer effects of DADS characterized.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- The anticancer effects of diallyl disulfide (DADS) have been further characterized. DADS, "one of the major components of garlic (Allium sativum), is well known to have chemopreventative activity...

New risks for bladder cancer identified by MIT team.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- MIT researchers and colleagues have identified three new chemical risk factors for bladder cancer in a study involving some 600 people in the Los Angeles area. The work was reported in the Journal...

Protein protecting brain from toxins also blocks some chemotherapy.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- St. Jude studies showing that Mrp4 limits penetration of topotecan suggest that blocking this protein might increase access of anticancer drugs to tumor sites and improve treatment of brain cancer ...

Exercise boosts recovery from cancer.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Women should aim for 1/2 hour of gentle exercise three times a week to aid their recovery from breast cancer, according to early results presented October 7, 2004, at a University of Bristol conference...

Fertility concerns affect treatment decisions of many young women with cancer.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Concern about infertility resulting from breast cancer therapy influenced treatment decisions in nearly one-third of young patients participating in a recent study. The study - the largest to date...

LifeShirt System measures cardiopulmonary parameters in breast cancer study.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Researchers at the Tom Baker Cancer Center and University of Calgary are using the LifeShirt System from VivoMetrics in combination with the Mindfulness Based Stress Reduction program (MBSR) to help...

Soy isoflavones in food, rather than pure form, better for ER-dependent disease.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Soy isoflavones in food, i.e., soy flour-containing foods, rather than isoflavones in pure form are better for women with estrogen-dependent breast cancer, recommend nutritionists at the University of...

Support groups aid women with BRCA1/2 gene mutations.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- A new study finds support groups can relieve the anxiety and depression associated with carrying BRCA1 or 2 gene mutations, the so-called "cancer genes." The results of the first study to...

Write-on T-shirt becomes diagnostic tool in fight against breast cancer.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- The fight against breast cancer has a new weapon: powerful, yet as easy to use as slipping on a T-shirt. The Mark for Life breast self-exam kit includes a unique form-fitting T-shirt with printed...

Young breast cancer patients concerned with therapy's effect on fertility.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- A new study shows that concern about infertility resulting from breast cancer therapy influenced treatment decisions in nearly one third of young patients. The study, which appears in the Journal of...

Healthcare company encouraged by NCI silicone gel-filled breast implants study.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- INAMED Corporation (IMDC) reported that they are encouraged by results published in the October 1, 2004, issue of the American Journal of Epidemiology in which researchers at the U.S. National Cancer...

Cancer research foundation announces new partnership.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- The Lance Armstrong Foundation (LAF) has announced a 5-year, $500,000 gift to the Nevada Cancer Institute (NVCI) to establish the Lance Armstrong Foundation Survivorship Center at the Institute. The new...

Contract research organization opens office in top German biotech region.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- INC Research has opened an office in Germany, in Dusseldorf's Life Science Center. INC Research strategically located its facility in the North Rhine-Westphalia region of Germany, to be in close...

Partnership formed to market phase 3 chemoprotective agent in North America.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Takeda Pharmaceutical Company Limited has entered into an alliance agreement with U.S. based BioNumerik Pharmaceuticals, Inc., to market Tavocept (dimesna), a phase 3 chemoprotective agent developed by...

American Indian summit aims to raise cancer awareness.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Health statistics show that once diagnosed with cancer, American Indians have a lower 4-year survival rate than any other group in the country. Organizers of the Northern Plains American Indian...

Pharmaceutical company enters licensing agreement to develop oral cancer drug.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- IVAX Corporation (IVX) has entered into a licensing agreement with Nippon Shinyaku to develop and market HMN-214, a polo-like kinase inhibitor that targets pancreatic, prostate, and a number of other...

Pharma company presented six studies at cancer therapy conference.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- PharmaMar presented data from six studies, four of which were from pharmacogenomics research projects at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics, held in...

Biliary excretion of imatinib mesylate and metabolite characterized.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- The biliary excretion of imatinib mesylate and its metabolite has been characterized. "Imatinib mesylate, licensed to treat chronic myelogenous leukemia and gastrointestinal stromal tumors, is...

Compounds with MDR1-enhanced anticancer activity identified.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Several novel anticancer compounds have demonstrated heightened activity in the presence of the MDR1 multidrug transporter. "For analysis of multidrug resistance, a major barrier to effective...

Data analysis confirms BrachySilTM is safe and effective at tumor regression.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Global nanotechnology company pSivida Limited (ASX: PSD) and Singapore General Hospital (SGH) are pleased to announce Interim data analysis from pSivida's phase IIA trial at SGH has confirmed...

Data supports value of prostate brachytherapy.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Recent data from a 12-year follow-up of more than 1,500 patients showed brachytherapy as a powerful treatment for prostate cancer. Dr. Louis Potters, medical director of the New York Prostate...

Emory announces first clinical use of Trilogy system for cancer treatment.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Emory University School of Medicine's department of radiation oncology has become the first cancer treatment center in the world to use the new Trilogy system from Varian Medical Systems (VAR), for...

Energy blocker kills big tumors in rats.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Building on their earlier work, Johns Hopkins researchers have discovered that an apparently nontoxic cellular "energy blocker" can eradicate large liver tumors grown in rats. Six months to more than a...

Flow cytometric assay provides measure of transient tumor hypoxia.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- A novel flow cytometric assay enables quantification of transient tumor hypoxia. "Transient hypoxia is a poorly understood and potentially important factor that may limit tumor response to various...

Fruit and veg extract enhances cancer drug.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- A food extract could be used to improve the effects of an established cancer drug, scientists report. The drug, mitomycin C (MMC), is a well-known anticancer treatment used mainly against solid...

Normal cells in tumors may aid cancer growth.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Normal cells that live among the cancer cells in a tumor may not be the innocent bystanders they are usually assumed to be. A study led by researchers at the Ohio State University Comprehensive...

Pharmaceutical company offers phase I trial update for DAVANAT.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Pro-Pharmaceuticals, Inc., (Amex:PRW) announced that a number of patients in its phase I clinical trial are receiving additional cycles (3, 4, & 5) of DAVANAT-1. DAVANAT-1 is a combination of DAVANAT...

Tumor regression reported with AP23573 in relapsed, refractory cancer.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Ariad Pharmaceuticals, Inc., (ARIA) announced, for the first time, updated results of two phase I clinical trials of its novel mTOR inhibitor, AP23573 as a single agent, showing documented tumor...

Biotech company receives $3 million NCI award for anticancer vaccine protein.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Stellar Biotechnologies, Inc. has been awarded $3 million from the National Cancer Institute of the [U.S.] National Institutes of Health for the development of production methods, quality standards, and...

New method identifies chromosome changes in malignant cells.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- In a boost to cancer research, Princeton scientists have invented a fast and reliable method for identifying alterations to chromosomes that occur when cells become malignant. The technique helps to...

Screening recommendations are met in only a few European countries.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Researchers with the Finnish Cancer Registry surveyed 25 cancer screening centers in 18 European countries and found that only a few follow recommended guidelines. According to A. Anttila and...

Socioeconomic disparities affect disease incidence and mortality in U.S.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Researchers with the U.S. National Cancer Institute (NCI) have identified time-related area socioeconomic disparities that affect cervical cancer incidence and mortality in the U.S. "Temporal...

Absolute guidelines needed for monitoring minimal residual disease in CML.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Absolute guidelines are needed for monitoring minimal residual disease in chronic myeloid leukemia. According to recent review in the journal Hematology, "Detection and monitoring of minimal...

Antitumor effects of thymidylate synthase inhibitors mediated by p21[superscript]Cip1.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- The cytotoxic effects of thymidylate synthase inhibitors on colon tumor cells are mediated by p21[superscript]Cip1. Researchers in Tennessee "demonstrated previously that interferon (IFN)-gamma...

CoFactor results reported showing antitumor activity, lower systemic toxicity.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Adventrx Pharmaceuticals, Inc., (ANX) announced the results of recent preclinical studies demonstrating enhanced antitumor activity with lower systemic toxicity in a mouse model for colorectal cancer...

Glutathione-S-transferase P1-1 may have role in early colon cancer.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Glutathione-S-transferase P1-1 may have role in early colon cancer. According to recent research from Japan, "aberrant crypt foci, precursors of colonic adenoma, are frequently positive for...

ZD9331 has minimal antitumor activity as 2[superscript]nd/3[superscript]rd line colorectal cancer therapy.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- ZD9331 yields minimal antitumor activity as a 2[superscript]nd or 3[superscript]rd line colorectal treatment. "This study investigated the efficacy, and tolerability of ZD9331 as second- or...

Genetic markers of therapeutic radiation sensitivity reviewed.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Known genetic biomarkers of therapeutic radiation sensitivity have been reviewed. "The occurrence of acute or late normal tissue reactions after therapeutic radiotherapy and cellular responses in in...

U.S. FDA grants orphan status to drug for treatment of soft tissue sarcoma.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- The United States Food & Drug Administration (FDA) has granted Orphan Drug Designation to Yondelis in the indication of soft tissue sarcoma (STS). The sponsor of this application in the U.S. is...

Health officials brief families on Pratt & Whitney cancer study.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Researchers say they will need nearly 3 more years to determine if the rate of brain cancer cases is above normal at jet-engine maker Pratt & Whitney. Gary Marsh, a biostatistician at the University...

Company announces clinical hold on TNFerade trials.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- GenVec (GNVC) announced that the U.S. Food and Drug Administration (FDA) has requested that clinical trials of TNFerade be placed on hold, pending review of information pertaining to a potential...

High serum SCC Ag predicts poor survival in esophageal cancer with esophagectomy.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Elevated serum levels of squamous cell carcinoma antigen predicts poor survival in advanced esophageal cancer after esophagectomy. According to recent research published in the World Journal of...

Interim results from TNFerade study presented at international cancer meeting.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- GenVec, Inc., (GNVC) announced that interim results from a phase II dose escalation study of TNFerade in esophageal cancer patients were presented at the 16th Symposium on "Molecular Targets and Cancer...

Gene profiling can distinguish intestinal and diffuse carcinomas.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Gene expression profiling may be useful for differentiating between intestinal and diffuse gastic cancers. "Gastric cancer is the fourth leading cause of cancer-related death in the world,"...

Inconsistent psychosocial outcomes among cancer services thwart comparison.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- A study comparing psychosocial outcomes of genetic counseling for familial cancers among five U.K. centers found the results too inconsistent to identify significant factors affecting service provision....

Protein patterns can be used to identify GBM subtypes.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Protein expression patterns can be used to identify subtypes of glioblastoma multiforme (GBM). According to recent research from the United States, GBM "has been subdivided into two types based on...

Gene expression patterns with prognostic value identified.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Gene expression profiles with prognostic value in hepatocellular carcinoma (HCC) have been identified. In a recent study, hepatologists in the United States, "analyzed global gene expression...

Drug receives orphan designation.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Medarex (MEDX) announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Medarex's fully human anti-CD30 antibody, MDX-060, for the treatment of Hodgkin's...

Cancer center utilizes new CT technology.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Siemens (SI) announced that the University of Texas M. D. Anderson Cancer Center will acquire five new CT systems, which will be installed in the new Ambulatory Care Building at the M.D. Anderson Cancer...

ANALYTIQ line of data aggregation, analysis, and reporting tools introduced.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- IMPAC Medical Systems, Inc., (IMPCE) announced the introduction of ANALYTIQ, IMPAC's line of data aggregation, analysis, and reporting tools. ANALYTIQ provides solutions that enable cancer care...

Isolated case of pulmonary KS in pregnancy reported.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Physicians at Northwestern University's Feinberg School of Medicine have described the first reported case of isolated pulmonary Kaposi's sarcoma in pregnancy. "Kaposi's sarcoma in human...

Estrogen plays a critical role in female hepatocarcinogenesis.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Estrogen plays a critical role in female hepatocarcinogenesis. According to researchers in Japan, "Estrogen has been related to the development of hepatocellular carcinoma (HCC). "In this...

Erbitux non-small cell lung cancer clinical development program advances.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- ImClone Systems Incorporated (IMCL) and Bristol-Myers Squibb (BMY) announced the advancement of the non-small cell lung cancer (NSCLC) clinical development program for Erbitux (Cetuximab), an IgG1...

Mobetron treatment system installed at Hospital San Jaime in Torrevieja, Spain.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Intraop Medical, Inc., has delivered and installed a Mobetron treatment system at Hospital San Jaime in Torrevieja, Spain. The Mobetron at San Jaime is the third Mobetron delivered to Europe and...

RAGE/cyclin B2 quotient useful for diagnosis.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- A novel assay may facilitate lung cancer diagnosis. "Simple tools for discrimination of lung tissues can be useful in a fast machine-aided diagnosis, for example, by tumor-specific microarrays,"...

Utility of gefitinib in NSCLC treatment reviewed.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- The utility of gefitinib treatment and other therapies for non-small-cell lung cancer (NSCLC) have been reviewed. NSCLC is "a leading cause of cancer-related mortality and, until screening detects...

T cells needed early in ASCT to induce a graft-versus-lymphoma effect.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- T cells are needed early in autologous stem cell transplantation in order to induce a graft-versus-lymphoma effect. According to recent research published in the journal Bone Marrow...

Cytostatic drugs enhance antitumor activity of anti-CD30 antibody.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Cytostatic drugs enhance the antitumor activity of an anti-CD30 antibody. "Due to its selective overexpression on the malignant cells of Hodgkin lymphoma (HL) and large cell anaplastic lymphoma...

Ki-67 expression determines rituximab efficacy in follicular lymphoma.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Ki-67 expression levels have a strong influence on the efficacy of rituximab therapy for follicular lymphoma (FL). "Rituximab is widely used for the treatment of B-cell non-Hodgkin lymphoma (NHL),...

Germline CDKN2A mutations rare in young patients.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Germline CDKN2A mutations are rare in children and adolescents with melanoma. "Early-onset melanoma under the age of 20 years is still a rare disease but has an increasing incidence," oncologists in...

Dendritic cell vaccine boosts T cell-mediated immunity to tyrosinase.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Vaccinia virus-transduced, CD34+-derived dendritic cell vaccination boosted T cell-mediated immunity to tyrosinase. Six American Joint Committee on Cancer stage IV melanoma patients were enrolled...

Telomere dynamics is prognostic factor for assessment of AML risk in MDS patient.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Telomere dynamics is a useful prognostic factor for the assessment of acute myelogenous leukemia risk in patients with myelodysplastic syndromes. According to recent research from Czech Republic,...

Anticancer agent may help induce cancer cell death.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Maxim Pharmaceuticals (MAXM) reported that in preclinical studies, its anticancer agent, MX22167, targets the transferrin receptor, leading to a previously unknown rapid induction of apoptosis. The...

Cancer research company receives grant to study cell-based cancer vaccine.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- MOLOGEN announced a grant from the Innovation Support Program of Berlin for the development of a cell-based, tumor-specific treatment for renal cell carcinoma. According to the announcement, MOLOGEN...

Gene profiling useful in sarcoma classification.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Gene expression profiling may facilitate sarcoma classification. "Sarcomas represent a heterogeneous group of diseases of a variety of recognized histologic types," scientists in the United States...

HCA and Tennessee Oncology form Sarah Cannon Research Institute.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- HCA and Tennessee Oncology, a large private oncology practice, have created the Sarah Cannon Research Institute, a new company that will increase the number of clinical trials for cancer patients. ...

Pharma companies announced research milestone in oncology therapeutic area.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Pharmacopeia Drug Discovery, Inc., (NASDAQ:PCOP) announced that another research milestone has been reached in its collaboration with Schering-Plough Corporation (NYSE:SGP) in the oncology therapeutic...

Pharma company acquires rites for Campto chemotherapy agent.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Pfizer announced that it has successfully completed the acquisition of rights to all assets relating to Campto (irinotecan hydrochloride injection), a chemotherapy agent for treatment of advanced...

Pre-clinical results show promise for cancer treatment.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- MorphoSys (MOR) presented preclinical results from its internal cancer antibody program, MOR202. MorphoSys said that the MOR202 antibodies were initially characterized in detail in various in vitro...

Cancer diagnostic company announces new research and development executive.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Matritech (MZT) announced the election of Gary Fagan, Ph.D., as vice president of research and development. Prior to this appointment, Fagan was Matritech's senior director of product development,...

Polio vaccines containing simian virus 40 may cause human cancer.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Scientists have found mixed evidence for a causal association between polio vaccines contaminated with simian virus 40 and cancer. According to published research from Canada, "In 1960, it was...

EPHB2 mutations linked to aggressive disease.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- EPHB2 mutations are associated with aggressive disease in prostate cancer patients. "The identification of tumor-suppressor genes in solid tumors by classical cancer genetics methods is difficult...

Genes linked to prostatic carcinogenesis identified.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Genes linked to the pathogenesis of prostate cancer (PC) have been identified. "To characterize the molecular feature in prostate carcitiogenesis and the putative transition from prostatic...

Mechanisms of perineural invasion elucidated.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- The molecular mechanisms of perineural invasion (PNI) in prostate cancer have been elucidated. PNI is "the major mechanism of prostate cancer spread outside the prostate," oncologists in Texas...

Novel method measures knowledge of prostate cancer screening risks/benefits.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- A novel method measures patient knowledge of prostate cancer screening risks and benefits. According to published research from the United States, "This manuscript describes the development and...

IMPAC enters sales consulting agreement.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- Elekta, a supplier of radiation oncology and neurosurgery solutions, and IMPAC Medical Systems, Inc., (IMPCE), a provider of information technology solutions for oncology care, have entered into a sales...

Largest-ever study of prostate brachytherapy reveals long-term success.
November 1, 2004... 2004 NOV 1 - (NewsRx.com & NewsRx.net) -- The results of the largest and most comprehensive study ever undertaken of permanent prostate brachytherapy, or "seed therapy," found overall survival rates for patients were equal to or better than...